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1. Introduction
1.1. Global aging
The aging of populations has become a worldwide phenomenon [1]. In 1990, 26 nations had
more than two million elderly citizens aged 65 years and older, and the projections indicate
that an additional 34 countries will join the list by 2030. In 2000, the number of old people
(65+ years) in the world was estimated to be 420 million and it was projected to be nearly
one billion by 2030, with the proportion of old people increasing from 7 to 12%. The largest
increase in absolute numbers of old people will occur in developing countries; it will almost
triple from 249 million in 2000 to an estimated 690 million in 2030. The developing regions'
sharing the worldwide aging population will increase from 59 to 71% [2]. Developed coun‐
tries, which have already shown a dramatic increase in people over 65 years of age will ex‐
perience a progressive aging of the elderly population. Underlying global population aging
is a process known as the “demographic transition” in which mortality and then fertility de‐
cline [3]. Decreasing fertility and lengthening life expectancy have together reshaped the age
structure of the population in most regions of the planet by shifting relative weight from
younger to older groups.
Both developed and developing countries will face the challenge of coping with a high fre‐
quency of chronic conditions, such as dementia, which is a characteristic of aging societies.
These conditions impair the ability of older persons to function optimally in the community
and reduce well-being among affected individuals and their families. Further, these condi‐
tions are associated with significant health care costs that must be sustained by the society at
large. Thus, the global trend in the phenomenon of population aging has a dramatic impact
on public health, healthcare financing and delivery systems throughout the world [4]. Due
to the aging of the population, dementia has become a major challenge to elderly care and
public health.
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1.2. Dementia and Alzheimer’s disease
Dementia is defined as a clinical syndrome, and characterized by the development of multi‐
ple cognitive deficits that are severe enough to interfere with daily functioning, including
social and professional functioning. The cognitive deficits include memory impairment and
at least one of the other cognitive domains, such as aphasia, apraxia, agnosia or disturbances
in executive functioning [5, 6]. Alzheimer’s disease is the most common cause of dementia
in the elderly, accounting for 60-70% of all demented cases [7]. Alzheimer’s disease is strictly
a neuropathological diagnosis determined by the presence of neurofibrillary tangles and se‐
nile plaques in the brain of patients with dementia. The disease frequently starts with mem‐
ory impairment, but is invariably followed by a progressive global cognitive impairment [8].
Vascular dementia is the second most common cause of dementia in the elderly after Alz‐
heimer’s disease. Vascular dementia is defined as loss of cognitive function resulting from
ischemic, hypoperfusive, or haemorrhagic brain lesions due to cerebrovascular disease or
cardiovascular pathology. Diagnosis of vascular dementia requires cognitive impairment;
vascular brain lesions, often predominantly subcortical, as demonstrated by brain imaging;
a temporal link between stroke and dementia; and exclusion of other causes of dementia [9].
The combination of Alzheimer’s disease and vascular dementia pathological changes in the
brains of older people are extremely common, making mixed dementia probably the most
common type of dementia [10].
Alzheimer’s disease was first identified more than 100 years ago, but research into its symp‐
toms, causes, risk factors and treatment has gained momentum only in the last 30 years. Al‐
though research has revealed a great deal about Alzheimer’s, the precise physiologic
changes that trigger the development of Alzheimer’s disease largely remain unknown. The
only exceptions are certain rare, inherited forms of the disease caused by known genetic mu‐
tations. Alzheimer’s disease affects people in different ways, but the most common symp‐
tom pattern begins with gradually worsening ability to remember new information. This
occurs because disruption of brain cell function usually begins in brain regions involved in
forming new memories. As damage spreads, individuals experience other difficulties. The
following are warning signs of Alzheimer’s disease: memory loss that disrupts daily life;
challenges in planning or solving problems; difficulty completing familiar tasks at home, at
work or at leisure; confusion with time or place; trouble understanding visual images and
spatial relationships; new problems with words in speaking or writing; misplacing things
and losing the ability to retrace steps; decreased or poor judgment; withdrawal from work
or social activities; and changes in mood and personality. As the disease progresses, the in‐
dividual’s cognitive and functional abilities decline. In advanced Alzheimer’s disease, peo‐
ple need help with basic activities of daily living, such as bathing, dressing, eating and using
the bathroom. Those in the final stages of the disease lose their ability to communicate, fail
to recognize loved ones and become bed-bound and reliant on around-the-clock care. When
an individual has difficulty moving because of Alzheimer’s disease, they are more vulnera‐
ble to infections, including pneumonia (infection of the lungs).
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2. Occurrence of Alzheimer’s disease
The occurrence of a disease can be measured as proportion of people affected by the disease
in a defined population at a specific time point (prevalence), or as number of new cases that
occur during a specific time period in a population at risk for developing that disease (inci‐
dence). The prevalence reflects the public health burden of the disease, whereas the inci‐
dence indicates the risk of developing that disease. The prevalence is determined by both
incidence and duration of the disease, and in certain circumstances, the prevalence may be
estimated as incidence × average disease duration.
2.1. Prevalence
Based on the available epidemiological data, a group of experts estimated that 24.3 million
people have dementia today, with 4.6 million new cases of dementia every year (one new
case every 7 seconds). The number of people affected will double every 20 years to 81.1 mil‐
lion by 2040 [11]. Similar estimates have been reported previously [12]. Most people with
dementia live in developing countries. China and its western Pacific neighbours have the
highest number of people with dementia (6 million), followed by the European Union (5.0
million), USA (2.9 million), and India (1.5 million). The rates of increase in the number of
dementia cases are not uniform across the world; numbers in developed countries are fore‐
casted to increase by 100% between 2001 and 2040, but to increase by more than 300% in In‐
dia, China, and other south Asian and western Pacific countries [11]. About 70% of these
cases were attributed to Alzheimer’s disease [11, 13]. The pooled data of population-based
studies in Europe suggests that the age-standardized prevalence in people 65+ years old was
6.4 % for dementia and 4.4 % for Alzheimer’s disease [14]. In the US, a study of a national
representative sample of people aged >70 years yielded a prevalence for Alzheimer’s disease
of 9.7 % [15].
Worldwide, the global prevalence of dementia was estimated to be 3.9 % in people aged 60+
years, with the regional prevalence being 1.6 % in Africa, 4.0 % in China and Western Pacific
regions, 4.6 % in Latin America, 5.4 % in Western Europe, and 6.4 % in North America [11].
A meta-analysis including 18 studies from China during 1990-2010 showed prevalence of
Alzheimer’s disease of 1.9% [16]. More than 25 million people in the world are currently af‐
fected by dementia, most suffering from Alzheimer’s disease, with around 5 million new
cases occurring every year [11]. The number of people with dementia is anticipated to dou‐
ble every 20 years. Despite different inclusion criteria, several meta-analyses and nationwide
surveys have yielded roughly similar age-specific prevalence of AD across regions (Figure
1) [17]. The age-specific prevalence of Alzheimer’s disease almost doubles every 5 years af‐
ter aged 65. Among developed nations, approximately 1 in 10 older people aged ≥ 65 is af‐
fected by some degree of dementia, whereas more than one third of very old people aged
≥85 years may have dementia-related symptoms and signs [18, 19]. There is a similar pattern
of dementia subtypes across the world, with Alzheimer’s disease and vascular dementia, the
two most common forms of dementia, accounting for 50 % to 70 % and 15 % to 25 %, respec‐
tively, of all dementia cases.
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Figure 1. Age-specific prevalence of Alzheimer's disease (per 100 population) across continents and countries. *preva‐
lence of all types of dementia [17].
Epidemiological research of dementia and AD in low- and middle-income countries has
drawn much attention in recent years. A systematic review estimated that the overall preva‐
lence of Alzheimer’s disease in developing countries was 3.4 % (95 % CI,1.6 % - 5.0 %) [20].
The prevalence of dementia (DSM-IV criteria) in people aged 65+ years in seven developing
nations varied widely from less than 0.5 % to more than 6 %, which is substantially lower
than in developed countries [21]. Indeed, the prevalence rates of dementia in India and rural
Latin America were approximately a quarter of the rates in European countries. However,
the prevalence of AD in persons 65+ years in urban areas of China was 3.5 %, and even high‐
er (4.8 %) after post-hoc correction for negative screening errors [22], which is generally
comparable with those from Western nations. Similar prevalence rates of dementia were al‐
so reported from the urban populations of Latin American nations such as Havana in Cuba
(6.4 %) and São Paulo in Brazil (5.1 %) [20, 23, 24].
2.2. Incidence
The global annual incidence of dementia is around 7.5 per 1,000 persons [11]. The incidence
rate of dementia increases exponentially with age, from approximately one per 1,000 person-
year in people aged 60-64 years to more than 70 per 1,000 person-year in 90+ year-olds. The
incidence rates of dementia across regions are quite similar in the younger-old (<75 years),
but greater variations are seen among the older ages [25]. Slightly lower rates have been de‐
tected in the USA in comparison with Europe and Asia, and this is possibly due to differen‐
ces in the study designs and the case ascertainment procedures. The pooled incidence rate of
Alzheimer’s disease among people 65+ years of age in Europe was 19.4 per 1000 person-year
[26]. The pooled data from two large-scale community-based studies of people aged ≥65
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years in the US Seattle and Baltimore areas yielded an incidence rate for Alzheimer’s disease
of 15.0 (male, 13.0; female, 16.9) per 1000 person-year [27, 28]. The incidence rate of Alzheim‐
er’s disease increases almost exponentially with increasing age until 85 years of age (Figure
2) [17]. A consistently exponential increase, with advancing age in Alzheimer incidence sug‐
gests that Alzheimer’s disease is an inevitable consequence of aging, whereas a convergence
to or a decline at certain age may suggest that very old people may have reduced vulnerabil‐
ity, owing perhaps to genetic or environmental factors. The Cache County Study further
found that the incidence of AD increased with age, peaked, and then started to decline at
extreme old ages for both men and women [29]. However, some meta-analyses and large-
scale studies in Europe provided no evidence for the potential decline in the incidence of de‐
mentia and Alzheimer’s disease among the oldest-old age groups [26, 30, 31]. The apparent
decline suggested in some studies may be an artifact of poor response rate and survival ef‐
fect in these very old age groups. Several studies from Europe observed a higher incidence
rate of Alzheimer’s disease among women than men, especially among the oldest-old age
groups, whereas studies in North America found no significant gender difference [17].
Figure 2. Age-specific incidence of Alzheimer's disease (per 1 000 person years) across continents and countries. *inci‐
dence of all types of dementia [17].
There appears to be some geographic variations in the incidence of Alzheimer’s disease. The
pooled data of eight European studies suggested a geographical dissociation across Europe,
with higher incidence rates being found among the oldest-old people of north-western
countries than among southern countries [26]. The incidence rates of Alzheimer’s disease
were reported to be slightly lower in North America than in Europe. Differences in method‐
ology (e.g., differences in study design and procedure of case ascertainment), rather than re‐
al different regional distributions of the disease, may be partly responsible for the
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geographic variations. The study using identical methods in UK found no evidence of varia‐
tion in dementia incidence among five areas in England and Wales [30]. Studies have con‐
firmed that AD incidence in developing countries is generally lower than in North America
and Europe. For example, the incidence rate of AD among people aged 65+ years was 7.7 per
1 000 person-year in Brazil and 3.2 per 1 000 person-year in India [20, 32].
3. Prognosis and impact
Dementia is one of the leading causes of death in older people. However, death certificates
grossly underreport its cause, even when multiple underlying causes of death are taken into
account. The community-based follow-up studies could provide reliable data on mortality.
In the Swedish Kungsholmen Project of people aged 75 years or over, the mortality rate of
dementia was 2.4 per 100 person-year; 70% of incident dementia cases died within five years
following the diagnosis. In three years, more than 50% of the dementia cases reached the se‐
vere stage. In the Kungsholmen Project, the proportion of severe dementia among prevalent
cases increased from 19% at baseline to 48% after three years, and to 78% after seven years.
This progression is due to both cognitive and functional decline [33]. Dementia is strongly
associated with disability as it has been found to be the major determinant of developing
dependence and functional decline over three years. Approximately half of the persons who
developed functional dependence in a three year period can attribute to dementia [34]. In
industrialised countries, mental disease and cognitive impairment are the most prevalent
disorders among older adults living in nursing homes or other institutions. However, insti‐
tutionalisation of demented patients varies depending on age structure, urban or rural resi‐
dence, and other cultural aspects. In a 75+ year old population, 70% of incident dementia
cases died in the five years following the diagnosis, accounting for a mortality rate specific
for dementia of 2.4 per 100 person-years. Dementia triples the risk of death [35]. The de‐
mands of healthcare and social service of the huge and rapidly growing numbers of demen‐
tia patients have a major economic impact at the societal level [36]. The worldwide direct
costs for dementia in 2003 were estimated at 156 billion USD in the main scenario of a
worldwide prevalence of 27.7 million demented persons. It is obvious that due to these costs
and the expected increase in the number of elderly people in developing countries, the de‐
menting conditions will present a great challenge [37,38].
4. Risk and protective factors
Alzheimer’s disease is multifactorial disorder that is determined by genetic and environ‐
mental factors as well as their interactions. Population-based prospective study is the major
epidemiological approach to identifying influential factors for chronic multifactorial diseas‐
es such as dementia, in which the life-course approach should be taken into consideration.
Age is the most powerful determinant of Alzheimer’s disease, and gene mutations contrib‐
ute to a small proportion of all cases. The strong association of Alzheimer’s disease with in‐
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creasing age may partially reflect the cumulative effect of different risk and protective
factors over the lifespan, including the effect of complex interactions of genetic susceptibili‐
ty, psychosocial factors, biological factors, and environmental exposures experienced over
the lifespan. Evidence from epidemiological, neuroimaging, and neuropathological research,
supports the role of genetic, vascular, and psychosocial factors in the development of Alz‐
heimer’s disease, whereas evidence for the etiologic role of dietary or nutritional factors, oc‐
cupational exposures, and inflammation is less clear [39].
4.1. Genetic factors
Mutations in amyloid precursor protein, presenilin-1, and presenilin-2 genes can cause ear‐
ly-onset familial Alzheimer’s disease that account for no more than 5% of all cases. The ma‐
jority of AD cases are sporadic, with considerable heterogeneity in their risk profiles and
neuropathological features.
4.1.1. Apolipoprotein E ε4 (APOE ε4)
The APOE ε4 allele is the only established susceptibility gene for both early- and late-on‐
set  Alzheimer’s  disease,  and  is  a  susceptibility  gene,  being  neither  necessary  nor  suffi‐
cient  for  the  development  of  Alzheimer’s  disease.  APOE  ε4  is  one  of  three  common
forms (ε2, ε3 and ε4) of the APOE gene, which provides the blue print for a protein that
carries  cholesterol  in  the  bloodstream.  Everyone  inherits  one  form  of  the  APOE  gene
from each parent. Those who inherit one APOE  ε4 gene have increased risk of develop‐
ing Alzheimer’s disease and of developing it at an earlier age than those who inherit the
ε2 or  ε3  forms of  the  APOE  gene [40].  Those who inherit  two APOE-ε4  genes  have an
even higher risk. Unlike inheriting a known genetic mutation for Alzheimer’s disease, in‐
heriting one or two copies of this form of the APOE gene does not guarantee that an in‐
dividual  will  develop  Alzheimer’s  disease.  The  risk  effect  of  the  APOE  ε4  allele
decreases with increasing age, and after age 75, 15–20% of Alzheimer’s cases are attribut‐
able to APOE  genotype [41].  Several other genes have been examined as possible candi‐
dates, but the reports are sporadic, and the results are inconsistent [42].
However, not all (4-carriers develop dementia. Studies have demonstrated that high educa‐
tion, active leisure activities, or maintaining vascular health seems to reduce the risk of de‐
mentia related to APOE ε4 [40, 41]. The ε4-carriers with these characteristics appear to have
similar dementia-free survival time to non ε4-carriers. Further, the obese related FTO gene
may interact with APOE ε4 to increase the risk of Alzheimer’s disease [44].
4.1.2. Family history
Individuals who have a parent, brother or sister with Alzheimer’s are more likely to develop
the disease than those who do not have a first-degree relative with Alzheimer’s [45-47].
Those who have more than one first-degree relative with Alzheimer’s disease are at even
higher risk of developing the disease [48]. When diseases run in families, heredity (genetics),
shared environmental and /or lifestyle factors or both may play a role.
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4.2. Biological risk factors
Increasing age is a well-established risk factor for Alzheimer’s disease. The incidence of Alz‐
heimer’s disease almost doubles with every 5 years of age [49, 50]. Female sex is often asso‐
ciated with an increased risk of AD, especially at the oldest-old age [25]. Men seem to be at
greater risk for vascular dementia than women [51].
4.3. Vascular disorders and risk factors
A number of vascular risk factors and disorders have been linked to Alzheimer’s disease,
but some factors may have a differential association with the risk of Alzheimer’s disease de‐
pending on the age when the exposure is assessed.
4.3.1. Blood pressure
Several studies have consistently reported an association between midlife high blood pres‐
sure and increased risk of dementia and Alzheimer's disease [52, 53]. Hypertension has been
linked to neurodegenerative markers in the brain, suggesting that long-term high blood
pressure may play a causal role in the neurodegenerative process itself or by causing brain
atrophy. In very old people, the deleterious effect of high blood pressure is less evident,
whereas low blood pressure seems to be predictive of dementia and Alzheimer’s disease. As
dementia has a long latent period, low blood pressure may be a sign of impending illness
[54], which was confirmed by the longitudinal data from the Kungsholmen Project, suggest‐
ing the involvement of late life low blood pressure and cerebral hypo-perfusion in the devel‐
opment of dementia and Alzheimer’s disease [55]. All these findings suggest that the
relation of blood pressure to dementia may be age-dependent [25].
Recent follow-up studies have suggested that the protective effect of antihypertensive thera‐
py on dementia and AD may depend on the duration of treatment and the age when people
take the medications; the more evident efficacy was seen among young-old people (i.e., <75
years) and those with long-term treatment [56, 57]. Evidence from clinical trials of antihy‐
pertensive therapy and dementia is summarized in the section on intervention trials to‐
wards primary prevention. Antihypertensive treatment may protect against dementia and
AD by postponing atherosclerotic process, reducing the number of cerebrovascular lesions,
and improving cerebral perfusion [52]. It has also been suggested that some antihyperten‐
sive agents (e.g., calcium-channel antagonists) may have neuroprotective effects. The recent
neuropathological study found substantially less Alzheimer neuropathological changes (i.e.,
neuritic plaque and neurofibrillary tangle densities) in the medicated hypertension group
than non-hypertensive group, which may reflect a salutary effect of antihypertensive thera‐
py against Alzheimer’s disease-associated neuropathology [57].
4.3.2. Cardiovascular disease
A healthy heart helps ensure that enough blood is pumped through blood vessels to the
brain. The follow-up data of the Cardiovascular Health Study showed that cardiovascular
disease was associated with an increased risk of Alzheimer’s disease, especially in people
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with peripheral arterial disease [58], suggesting that extensive peripheral atherosclerosis is a
risk factor for Alzheimer’s disease. Other cardiovascular diseases, such as heart failure and
atrial fibrillation, have been independently related to increased risk of dementia. In the
Kungsholmen Project, heart failure was associated with a more than 80% increased risk of
dementia and Alzheimer’s disease [59].
4.3.3. Cerebrovascular disease
Cerebrovascular changes such as haemorrhagic infarcts, small and large ischemic cortical in‐
farcts, vasculo-pathie, and white matter changes all increase the risk of dementia [13]. Sys‐
tematic reviews of population-based studies reveal an approximately two- to four-fold
increased risk of incident dementia associated with clinical stroke (post-stroke dementia).
Multiple cerebral infarcts, recurrent and strategic strokes are main risk factors for post-
stroke dementia. Silent stroke and white matter lesions detected on neuroimaging are asso‐
ciated with increased risk of dementia and cognitive decline. Spontaneous cerebral emboli
were related to both AD and VaD. Some studies reported an association of stroke with Alz‐
heimer’s disease and cognitive decline [60]. Cerebral vascular lesions may interact with neu‐
rodegenerative lesions to produce a dementia syndrome in individuals not having sufficient
neurodegenerative damages to express dementia [25]. Neuropathological studies suggested
that cerebrovascular lesions, atherosclerosis, and neurodegenerative changes in the brain of‐
ten coexist, and may be coincident processes converging to cause additive damage to the ag‐
ing brain and to promote clinical expression of the dementia syndrome [61].
4.3.4. Diabetes mellitus
A potential link between diabetes and cognitive impairment was first reported more than 80
years ago. The association of diabetes with these cognitive changes is now well established
[62]. There is substantial evidence suggesting that type 2 diabetes is associated with cogni‐
tive impairment involving both memory and executive function [63-65]. Several large longi‐
tudinal population-based studies have also shown that the rate of cognitive decline is
accelerated in elderly people with type 2 diabetes [66]. An increased risk of not only vascu‐
lar dementia but also neurodegenerative type dementia among persons with diabetes has
been reported in several longitudinal studies [67-70], and the risk effect was confirmed by a
systematic review [71]. Midlife diabetes or a longer duration of diabetes may play a crucial
role in dementia and Alzheimer’s disease [68, 72]. Overall, diabetes leads to a 20-70% greater
decline in cognitive performance, and a 60% higher risk of dementia [73]. In addition, bor‐
derline or prediabetes or impaired glucose tolerance, is also linked to an increased risk of
dementia and Alzheimer’s disease in very old people [74].
4.3.5. Overweight and obesity
Similar to hypertension, recent studies suggested a lifespan-dependent relation of obesity
with dementia [75, 76]. A higher body mass index (BMI) at middle age was related to an in‐
creased risk of dementia in late life [77, 78]. A greater decline in BMI approximately 10 years
prior to dementia onset was detected, which is in line with the other studies suggesting an
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association of accelerated BMI decline with Alzheimer’s disease [79, 80]. Low BMI in late life
and weight loss may be related to high risk of dementia and Alzheimer’s disease [81], but
low BMI and weight loss can be interpreted as markers of preclinical Alzheimer’s disease,
especially when measured less than 10 years prior to clinical diagnosis [25]. In line with
these findings, several follow-up studies of older people suggested that accelerated decline
in BMI was associated with future development of Alzheimer’s disease [79, 82, 83]. Low
BMI in late life was related to a higher risk for Alzheimer’s disease over a subsequent 5- to 6-
year period [81]. Thus, late-life low BMI and weight loss can be interpreted as markers for
preclinical Alzheimer’s disease, particularly when measured just a few years prior to clinical
diagnosis of the disease [17].
4.3.6. Hyperlipidaemia
An association of elevated cholesterol at middle life with increased risk of late-life Alzheim‐
er’s disease was reported in some studies [53]. Controversial findings have also been report‐
ed on the relation of cholesterol in late life to dementia risk. Some cohort studies found no
association or even an inverse association of total cholesterol with dementia risk [84]. A
study showed a decline in total cholesterol at least 15 years before dementia onset [85]. Re‐
cently, a bidirectional cholesterol-cognition relationship has been reported. High midlife
cholesterol was associated with poorer late-life cognition, but decreasing cholesterol after
midlife may reflect poorer cognitive status [86].
4.3.7. The metabolic syndrome
Instead of exploring the effect of its subcomponents, several studies have assessed the rela‐
tionship between metabolic syndrome as a whole and the risk of Alzheimer’s disease or cog‐
nitive decline. A clustering of interrelated metabolic risk factors such as diabetes, obesity,
hypertension and dyslipidaemia has received increasing attention in the past few years. Sev‐
eral components of the metabolic syndrome have been individually related to cognitive out‐
comes. A prospective study found that the metabolic syndrome contributed to cognitive
decline [87]. But this finding was not confirmed in a population of the oldest old. The con‐
cept of the metabolic syndrome may be less valid in this age group [88]. Finally, two studies
showed that metabolic syndrome was associated with an increased risk of Alzheimer’s dis‐
ease [89, 90].
4.3.8. Alcohol consumption
Excessive alcohol intake can cause alcoholic dementia and may increase the risk of vascular
dementia. Heavier alcohol intake at middle age was associated with increased risk of late-
life dementia [91]. By contrast, increasing evidence suggests that light to moderate alcohol
consumption may be associated with a reduced risk of dementia and cognitive decline [92],
a similar effect as observed for cardiovascular disease [25]. In a meta-analysis of 15 prospec‐
tive studies on the effect of alcohol on dementia risk, light to moderate alcohol consumption
was associated with a reduction in the risk of Alzheimer’s disease and dementia [93]. How‐
ever, the role of moderate alcohol consumption in dementia still remains controversial be‐
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cause the inverse association may be due to information bias, the confounding of healthy
lifestyles and high socioeconomic status, different approaches in assessments of alcohol con‐
sumption, or outcome misclassification.
4.3.9. Cigarette smoking
The relationship between smoking and cognitive decline remains uncertain. Case-control
studies have largely suggested that smoking lowers the risk of Alzheimer’s disease [13].
Some prospective studies have found an increased risk of Alzheimer’s disease associated
with smoking [94]. A meta-analysis that examined the association between smoking and
Alzheimer’s disease while accounting for tobacco-industry affiliation found that the com‐
bined results of 18 cross-sectional studies without industry affiliations yielded no associa‐
tion [95]. Analysis of 14 cohort studies without tobacco-industry affiliations yielded a
significant increase in the risk of Alzheimer’s disease [13]. In the Kungsholmen Project,
smoking affected survival in Alzheimer’s disease cases more than in non-demented subjects,
and the protective effect of smoking on the Alzheimer’s disease was no longer present when
incident Alzheimer’s cases were studied [7] suggesting that previously reported association
of cigarette smoking with low prevalence of dementia was probably due to survival bias.
4.3.10. Diet and nutrients
Diets high in fish, fruits and vegetables are high in anti-oxidants and polyunsaturated fatty
acids (PUFAs). In some observational studies, high or supplementary intake of vitamins C,
E, B6, B12, and folate has been related to a decreased risk of Alzheimer’s disease [96, 97].
Indeed, low levels of B12 and folate were found to be related to an increased risk of Alz‐
heimer’s disease in a study from the Kungsholmen Project [98]. Investigations on the effect
of dietary PUFAs on the risk of cognitive dysfunction proved inconclusive. Several studies
showed that the consumption of PUFAs led to reduction in the risk of Alzheimer’s disease
and dementia, mild cognitive impairment [99]. Population-based studies suggested that
moderate to high intake of unsaturated fats at midlife is protective, whereas a moderate in‐
take of saturated fats may increase the risk of dementia and Alzheimer’s disease [100, 101],
especially among APOE ε4 carriers [102, 103]. Fatty acids may affect dementia through vari‐
ous mechanisms such as atherosclerosis and inflammation. Adherence to ‘Mediterranean di‐
et’ (higher intake of fish, fruits, and vegetables rich in antioxidants) was associated with a
reduced risk of Alzheimer’s disease independent of vascular pathways [104].
4.4. Psychosocial factors
Psychological factors include social economic status, education attainment in early life, and
work complexity in adult-life and leisure activities. Evidence from epidemiological research
has been accumulating that some psychosocial factors and healthy lifestyle may postpone
the onset of dementia, possibly by enhancing cognitive reserve.
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4.4.1. Social economic status
A number of studies have found that higher socioeconomic status (SES) is associated with a
reduced risk of developing Alzheimer’s disease [105-107]. In most of these studies, SES was
assessed based on occupational attainment, current income to reflect socioeconomic level in
adulthood, or educational attainment. Findings from a prospective study, however, suggest‐
ed that early life socioeconomic status assessed at the household or community level was re‐
lated to level of cognition in late life but not to rate of cognitive decline or risk of
Alzheimer’s disease [47].
4.4.2. High education
Numerous longitudinal studies have consistently shown that a higher educational achieve‐
ment in early life is associated with a decreased incidence of dementia, and of Alzheimer’s
disease in particular. Low dementia prevalence among highly educated persons has been re‐
ported by numerous surveys. Educational attainment and lifespan mental activity associat‐
ed with childhood education may reduce the risk of dementia [25]. The cogntive reserve
hypothesis has been proposed to interpret this association such that education could en‐
hance neural and cognitive reserve that may provide compensatory mechanisms to cope
with degenerative pathological changes in the brain, and therefore delay onset of the de‐
mentia syndrome [17]. Alternatively, educational achievement may be a surrogate or an in‐
dicator of intelligent quotient, early life living environments, and occupational toxic
exposure experienced over adulthood [108].
4.4.3. Physical activity
Basic science and observational evidence on humans strongly supports the hypothesis that
increased physical activity prevents the onset of dementia. Regular exercise, even low-inten‐
sity activity such as walking, has been associated with reduced risk of dementia and cogni‐
tive decline [109-111]. In the Kungsholmen Project, the component of physical activity
presenting in various leisure activities, rather than sports and any specific physical exercise,
was related to a decreased dementia risk [110]. A strong protective effect of regular physical
activity in middle age against the development of dementia and Alzheimer’s disease in late
life was reported, especially for persons with the APOE ε4 allele [112]. As it may take years
to achieve high levels of physical fitness, brief periods of exercise training may not have sub‐
stantial benefits on cognitive processes, but could still be detectable in the subsets of cogni‐
tive domains that are more sensitive to the age related decrements. Physical activity is
important not only in promoting general and vascular health, but also in promoting brain
plasticity, and it may also affect several gene transcripts and neurotropic factors that are rel‐
evant for the maintenance of cognitive functions. There is now increasing amounts of trial
evidence to support this hypothesis in terms of cognitive benefits in healthy older adults as
well as in people at risk for dementia. However, to date there are no RCTs confirm that in‐
creased physical activity prevents dementia.
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4.4.4. Mentally stimulating activity
Various types of mentally demanding activities have been examined in relation to dementia
and AD, including knitting, gardening, dancing, playing board games and musical instru‐
ments, reading, social and cultural activities, and watching specific television programs,
which often showed a protective effect [113]. Due to the cultural and individual differences
in choosing specific activities, some researchers summarize mentally stimulating activities
into a composite score, which showed that a cognitive activity score involving participation
in seven common activities with information processing as a central component was associ‐
ated with a reduced risk of AD, even after controlling for APOE ε4 allele, medical condi‐
tions, and depressive symptoms [114, 115]. The Swedish Twin Study showed that greater
complexity of work, and particularly complex work with people, may reduce the risk of Alz‐
heimer’s disease [116]. The Canadian Study of Health and Aging found that high complexi‐
ty of work appeared to be associated with a reduced risk of dementia, but mostly for
vascular dementia [117]. In supporting of these findings, the recent neuroimaging study
suggested that a high level of complex mental activity across the lifespan was correlated
with a reduced rate of hippocampal atrophy [118].
4.4.5. Social network and social engagement
A poor social network or social disengagement in late life was associated with an elevated
risk of dementia. Evidence from longitudinal observational studies suggests that a poor so‐
cial network or social disengagement is associated with cognitive decline and dementia [119,
120]. The risk for dementia and AD was also increased in older people with increasing social
isolation and less frequent and unsatisfactory contacts with relatives and friends. Further‐
more, low social engagement in late life and a decline in social engagement from middle age
to late life were associated with a doubly increased risk of developing dementia and AD in
late life. Rich social networks and high social engagement imply better social support, lead‐
ing to better access to resources and material goods [123]. Rich and large social networks al‐
so provide affective and intellectual stimulation that could influence cognitive function and
different health outcomes through behavioural, psychological, and physiological pathways
[122]. Finally, a recent study suggested that low neuroticism in combination with high extra‐
version was the personality trait associated with the lowest dementia risk, and among so‐
cially isolated individuals even low neuroticism alone seemed to decrease the risk of
dementia [121].
4.4.6. Depression
Recent evidence suggests a strong relationship between depression and Alzheimer's disease.
A lifetime history of major depression has been considered as a risk factor for later develop‐
ment of Alzheimer's disease [124, 125]. The presence of depressive symptoms can affect the
conversion of mild cognitive impairment to Alzheimer's disease. Neuronal plaques and neu‐
rofibrillary tangles, the two major hallmarks of Alzheimer's disease brain, are more pro‐
nounced in the brains of Alzheimer's disease patients with comorbid depression as
compared with Alzheimer's disease patients without depression. On the other hand, neuro‐
Epidemiology of Alzheimer’s Disease
http://dx.doi.org/10.5772/54398
341
degenerative phenomena have been observed in different brain regions of patients with a
history of depression. Recent evidence suggests that molecular mechanisms and cascades
that underlie the pathogenesis of major depression, such as chronic inflammation and hy‐
per-activation of hypothalamic–pituitary–adrenal (HPA) axis, are also involved in the
pathogenesis of Alzheimer's disease [125]. A recent study has shown that depression in‐
creased the risk of dementia among patients with diabetes [126].
4.5. Other factors
4.5.1. Inflammation
Inflammation is known to be involved in the atherosclerotic process. Thus, serum inflamma‐
tory makers may be associated with dementia. Some cohort studies found such an associa‐
tion, and C-reactive protein may be the most promising in predicting dementia risk [127]. In
addition, long-term use of non-steroidal anti-inflammatory drugs was suggested to be asso‐
ciated with a lower risk of AD [25].
4.5.2. Hormone replacement therapy
Hormone replacement therapy in postmenopausal women has been frequently reported to
be associated with a lower risk of AD. An association between hormone replacement thera‐
py and a reduced risk of dementia and Alzheimer’s disease among postmenopausal women
had been frequently reported in numerous observational studies until 2004 when, instead of
a protective effect, a significantly increased risk of dementia associated with estrogenic ther‐
apy was found in the Women's Health Study [128].
4.5.3. Occupational exposures
Manual work involving goods production has been associated with an increased risk of AD
and dementia. Occupation and occupational exposures (e.g., electromagnetic fields and
heavy metals) may play a role in dementia and Alzheimer’s disease [129, 130]. Data from the
Kungsholmen Project showed that manual work involving goods production was associated
with an increased risk of dementia and Alzheimer’s disease [130], and specifically a risk ef‐
fect was detected with electromagnetic exposure [129]. Occupational exposure to extremely-
low-frequency electromagnetic fields (ELF-EMF) has been related to an increased risk of
dementia and AD in a number of follow-up studies [129, 131]. The meta-analysis of epide‐
miological evidence suggests an association between occupational exposure to ELF-EMF
and AD [132].
4.5.4. Head trauma and traumatic brain injury
For many years, head trauma has been suggested as a possible risk factor for Alzheimer’s
disease, and it has been extensively investigated in several studies, but this possible associa‐
tion still remains controversial. Moderate head injuries are associated with twice the risk of
developing Alzheimer’s compared with no head injuries, and severe head injuries are asso‐
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ciated with 4.5 times the risk [133, 134]. Moderate head injury is defined as a head injury
resulting in loss of consciousness or post-traumatic amnesia lasting more than 30 minutes; if
either of these lasts more than 24 hours, the injury is considered severe. These increased
risks have not been shown for individuals experiencing mild head injury or any number of
common mishaps, such as bumping one’s head while exiting a car. Groups that experienced
repeated head injuries, such as boxers, football players and combat veterans, may be at in‐
creased risk of dementia, late-life cognitive impairment and evidence of tau tangles (a hall‐
mark of Alzheimer’s) at autopsy [135-138]. Additional research is needed to better
understand the association between brain injury and increased risk of Alzheimer’s disease.
5. Summary of evidence from systematic review
Meta-analyses and systematic reviews have provided robust evidence that cognitive reserve
(a concept combining the benefits of education, occupation, and mental activities) [139],
physical activity and exercise [140, 141], midlife obesity [142], alcohol intake [93], and smok‐
ing [142] are the most important modifiable risk factors for Alzheimer's disease. There is in‐
sufficient overall evidence from epidemiological studies to support any association between
dietary or supplementary antioxidant or B vitamins and altered risk of incident dementia
[143, 144]. Data from several independent time points from a large Swedish epidemiological
study suggest that better social networks and social activities might be associated with re‐
duced incidence of Alzheimer's disease [119], but this has not been examined systematically
in other large epidemiological cohorts [61].
Many treatable medical conditions have also been associated with an increased risk of Alz‐
heimer's disease, including stroke [145], diabetes [146], midlife hypertension [52], and mid‐
life hypercholesterolemia [147, 148]. Blood pressure and cholesterol both seem to be reduced
in late life and in the prodromal to Alzheimer's disease; thus, the difference between midlife
and late life is an important distinction. There is probably an important relation between
some of these conditions and the lifestyle factors mentioned previously, and interventions to
promote healthy living will probably reduce the incidence of diabetes and stroke as well as
having other, more direct, effects on dementia. There is limited evidence about the potential
effect of management of diabetes or stroke on the risk of subsequent dementia, more inter‐
vention trials on this topic are needed (Table 1) [61,149].
Less than two decades have passed since the first incidence data for Alzheimer's disease and
other dementias were reported, during which there have been many achievements in the
understanding of risk and protective factors of Alzheimer’s disease. Accumulated evidence
from epidemiological research strongly supports a role for lifestyle and cardiovascular risk
factors in the pathogenesis and development of dementia. However, none of these factors
has been proven to have a causal relation specifically with Alzheimer’s disease. Indeed, this
topic is further complicated by the fact that the traditional diagnosis of dementia subtypes
has been challenged by population-based neuropathological and neuroimaging studies. Re‐
search has shown a range of dementia-associated brain abnormalities from pure vascular le‐
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sions at one end to pure Alzheimer's pathologies at the other, with most dementia cases
being attributable to both vascular disease and neurodegeneration.
Factors Systematic review Results
Overweight and obe‐
sity
Meta-analysis of ten studies. Sixteen articles on
15 prospective studies with 3.2-36 years follow-
up
Overweight: Dementia RR 1.26 (95% CI 1.10–1.44); Alz‐
heimer's disease 1.35 (95% CI 1·19–1.54)
Obesity: Dementia RR 1.64 (95% CI 1.34-2.00); Alz‐
heimer’s disease RR 2.04 (95% CI 1.59-2.62)
Smoking Meta-analysis of four prospective studies with
2–25 years follow-up in over 17 000 people. In
the four studies the dementia ORs were 3·17
(95% CI 1.37–7.35), 1.42 (1.07–1.89), 1.60
(1.00–2.57), and 1.63 (1.00–2.67)
Dementia RR 2.2 (95% CI 1.3–3.6)
Physical activity 13 prospective studies focusing on Alzheimer's
disease, dementia, or both, with at least 150
000 participants
Dementia RR 0.72 (95% CI 0.60–0.86); Alzheimer's dis‐
ease 0.55 (95% CI 0.36–0.84)
Cognitive reserve (in‐
telligence, occupa‐
tion, and education)
22 prospective studies with at least 29 000 par‐
ticipants followed up for a median of 7.1 years
Dementia OR 0.54 (95% CI 0.49–0.59)
Alcohol 15 longitudinal studies with 2–8 years follow-
up and at least 14 000 participants
Dementia RR 0.74 (95% CI 0.61–0.91); Alzheimer's dis‐
ease 0.72 (0.61–0.86)
Medical conditions
Midlife hypertension At least 15 years follow-up in most studies,
with at least 16 000 participants
Four of five longitudinal studies focusing on midlife hy‐
pertension suggested that it is a significant risk factor
for incident dementia (RR 1.24–2.8 in different studies)
The biggest differences were reported in studies using
160/95 mm Hg as the threshold for hypertension
Stroke 16 studies with at least 25 000 participants,
mainly included patients aged 65 years and
over
12 of 16 studies showed significant association be‐
tween stroke and incident dementia, with overall dou‐
bling of incidence
Diabetes 15 prospective cohort studies Dementia RR 1.47 (95% CI 1.25–1.73); Alzheimer's dis‐
ease RR 1.39 (95% CI 1.16–1.66)
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Factors Systematic review Results
Midlife hypercholes‐
terolemia
18 studies, but only five assessed high choles‐
terol specifically in midlife. All five midlife stud‐
ies had over 15 years follow-up and a total of
over 15 000 participants
Four of five longitudinal studies in midlife suggested a
significant positive association between high total cho‐
lesterol and incident dementia. For overall difference
the RR was 1·4–3·1
Intervention studies
Hypertension 12 091 participants between the three trials
(SHEP, SYST-EUR, and SCOPE) with mean fol‐
low-up of 3·3 years. Only SYST-EUR reported
significant benefit
OR 0.89 (95% CI 0.69–1.16) for incident dementia
Statins for prevention
of dementia
26 340 participants between the two trials
(PROSPER and HPS), with follow-up of 3·2 and
5 years. Cognition was measured with different
instruments at different timepoints
Neither of the two trials reported significant benefit of
statin therapy
Vitamins B12 or fo‐
late
Four trials in older people without existing cog‐
nitive impairment
Three trials showed no benefit. One trial (the only that
selected participants based on increased homocys‐
teine) reported benefit with respect to global function
RR=relative risk. OR=odds ratio. SHEP=Systolic Hypertension in the Elderly Program. SYST-EUR=Systolic Hypertension in
Europe. SCOPE=Study on Cognition and Prognosis in the Elderly. PROSPER=PROspective Study of Pravastatin in the
Elderly at Risk. HPS=Heart Protection Study.
Table 1. Meta-analyses or systematic reviews of risk factors for dementia and Alzheimer's disease [61,149]
Population studies have identified many factors that could be important in reducing the risk
of dementia, including factors that identify people at risk for dementia (vascular risk factors,
depressive symptoms) and factors that may reduce the risk of dementia (cognitive, physical,
and social activity, a diet rich in antioxidants and polyunsaturated fatty acids, vascular risk
factor control). While early interventional studies have been less conclusive, future trials
should continue to examine the effect of risk factor modification on cognitive outcomes. In
particular, interventions that combine a number of factors, such as healthy nutrition along
with cognitive, social, and physical activity, should be investigated. In the most optimistic
view, dementia could be delayed or even prevented by these interventions. At worst, people
will improve their overall health, especially their cardiovascular health, and enjoy a more
cognitively and socially engaging life.
5.1. Intervention strategies against Alzheimer’s disease
Despite the specific challenges posed by neurological disorders, such as Alzheimer’s disease
and other dementias, interventions need to be implemented to verify findings from the
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many population-based observational studies, which suggest that preventive and therapeu‐
tic interventions have great potential [150].
5.1.1. Vascular factors and related disorders
Most vascular risk factors and related disorders are modifiable or treatable that can serve as
targets in the development of primary preventative strategies against dementia. For exam‐
ple, antihypertensive therapy has been shown to reduce the risk of dementia in observatio‐
nal studies, and this finding was partly confirmed by clinical trials. Furthermore, studies
have confirmed that obesity and diabetes can be prevented by changing dietary habits and
lifestyles, and that health education may help quit smoking. Finally, preventing recurrent
cerebrovascular disease and maintaining sufficient cerebral blood perfusion seems to be crit‐
ical for postponing expression of the dementia syndrome in older people. Thus, controlling
high blood pressure and obesity, especially from middle age, and preventing diabetes and
recurrent stroke could be the primary preventive measures against late-life dementia.
5.1.2. Intervention towards psychosocial factors and lifestyles
High educational achievements in early life can provide cognitive reserve that benefits the
whole life in terms of cognitive health and delaying the onset of late-life dementia. Extensive
social networks and active engagements in intellectually stimulating activities such as read‐
ing, doing crosswords, and playing board games may significantly lower the risk of demen‐
tia by providing cognitive reserve or by reducing psychosocial stress. It is likely that
mentally and socially integrated lifestyles could postpone the onset of dementia [119]. Regu‐
lar physical exercise may reduce the risk of the dementias resulting from cerebral atheroscle‐
rosis. Leisure activities with all three components of physical, mental, and social activities
may have the most beneficial effect on dementia prevention. Many of the risk factors for de‐
mentia, such as hypertension, diabetes, and obesity, may be modified by diet. In addition, a
diet high in antioxidants may reduce inflammation, which is associated with the risk of de‐
mentia. Thus, it is reasonable to suggest that the risk of dementia itself could be modified by
diet. The treatment of depression also seems to improve cognitive function in people who
are depressed. Taking together, the most promising strategy for the primary prevention of
dementia may be to encourage people implementing multiple preventative measures
throughout the life course, including high educational attainment in childhood and early
adulthood, an active control of vascular factors (e.g., smoking) and disorders (e.g., hyperten‐
sion and diabetes) in adulthood, and maintenance of mentally, physically, and socially ac‐
tive lifestyles during middle age and later in life.
6. Conclusions
Alzheimer’s disease is a major cause of functional dependence, institutionalisation, and
mortality among elderly people. Population-based studies have made a great contribution to
our knowledge of Alzheimer’s disease. Although many aspects of Alzheimer’s disease are
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still unclear, we are now able to make more accurate diagnoses than before, and the pattern
of dementia distribution has been sufficiently described to guide the planning of medical
and social services. Epidemiological studies have shown that vascular risk factors in middle
age and later in life significantly contribute to the development and progression of the de‐
mentia syndrome, whereas extensive social network and active engagement in social, physi‐
cal, and mental activities may delay the onset of the dementing disorders. Hence, one of the
promising strategies to deal with the tremendous challenge from the epidemic of dementia
is to implement appropriate intervention measures from a life-course perspective. Achieving
high education in early life and engaging mentally stimulating activity over adulthood to
enhance cognitive reserve, and maintaining vascular health by adopting healthy lifestyles
and optimally controlling vascular diseases to reduce the burden of vascular lesions in the
brain. These preventive measures will enable people to maintain cognitive ability in late life,
even though they may have developed a high load of Alzheimer pathologies in their brain.
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